Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Gabrielle Leclercq-CohenHélène HaegelAnneliese SchneiderAnna Maria GiustiEstelle Marrer-BergerChristophe BoetschAntje-Christine WalzVesna PulkoJohannes SamJohn ChallierCristiano FerliniAlex OdermattPablo UmañaMarina BacacChristian KleinPublished in: Journal for immunotherapy of cancer (2022)
Taken together, we provide evidence for the use of dasatinib as a pharmacological on/off switch to mitigate off-tumor toxicities or CRS by T cell bispecific antibodies.
Keyphrases